Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus - 21/09/22
Doi : 10.1016/j.jbspin.2022.105381
Wietske M. Lambers a, ⁎ 
, Johanna Westra a, Suzanne Arends a, Berber Doornbos - van der Meer a, Barbara Horvath b, Hendrika Bootsma a, Karina de Leeuw a
, Johanna Westra a, Suzanne Arends a, Berber Doornbos - van der Meer a, Barbara Horvath b, Hendrika Bootsma a, Karina de Leeuw a a Departments of Rheumatology & Clinical Immunology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
b Departments of Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
⁎Corresponding author.
Highlights |
• | In this longitudinal study 18% of patients with incomplete Systemic Lupus Erythematosus developed classified disease in median 36months follow-up. |
• | IFN-type I gene expression is a risk factor for progression to Systemic Lupus Erythematosus or primary Sjögren's Syndrome. |
• | This study demonstrates that persistent low levels of complement 3 and complement 4 are associated with progression to classified disease. |
Keywords : Systemic lupus erythematosus, Primary Sjögren's disease, Biomarker, interferon, Complement
Mappa
© 2022
Société française de rhumatologie. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 89 - N° 5
Articolo 105381- ottobre 2022 Ritorno al numero
Articolo precedente
- Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: A cross-sectional analysis
- Florian Lucasson, Andra Balanescu, Uta Kiltz, Ying-Ying Leung, Sibel Zehra Aydin, Inna Gaydukova, Ennio Lubrano, Laura C. Coates, Maarten de Wit, Ana-Maria Orbai, Laure Gossec
- Urolithiasis in ankylosing spondylitis: A meta-analysis
- Océane Henares, Arnaud Pflimlin, Xavier Romand, Athan Baillet
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?